Document ID: FDA-2007-N-0377-0004
Agency: fda
Document Type: Notice
Title: Allyn M. Norman; Debarment Order
Posted Date: 2009-06-12T04:00Z

[Federal Register: June 12, 2009 (Volume 74, Number 112)]
[Notices]               
[Page 28050]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr12jn09-68]                         

[[Page 28050]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-N-0377] (formerly Docket No. 2007N-0299)

 
Allyn M. Norman; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is issuing an order 
under the Federal Food, Drug, and Cosmetic Act (the act) debarring Dr. 
Allyn M. Norman for 5 years from providing services in any capacity to 
a person that has an approved or pending drug product application. FDA 
bases this order on a finding that Dr. Norman was convicted of a 
misdemeanor under Federal law for conduct relating to the development 
or approval, including the process for development or approval, of a 
drug product or otherwise relating to the regulation of drug products 
under the act, and that the type of conduct that served as the basis 
for the conviction undermines the process for the regulation of drugs. 
Dr. Norman failed to request a hearing and, therefore, has waived his 
opportunity for a hearing concerning this action.

DATES:  This order is effective June 12, 2009.

ADDRESSES:  Submit applications for termination of debarment to the 
Division of Dockets Management (HFA-305), Food and Drug Administration, 
5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:  Robert L. Hummel, Sr., Division of 
Compliance Policy (HFC-230), Office of Enforcement, Office of 
Regulatory Affairs, Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 240-632-6845.

SUPPLEMENTARY INFORMATION:

I. Background

    On October 28, 2002, the U.S. District Court for the Western 
District of New York accepted Dr. Norman's plea of guilty to one count 
of failure to maintain adequate and accurate records relating to the 
use of investigational new drugs, a Federal misdemeanor offense under 
21 U.S.C. 331(e) and 333(a)(1). On February 5, 2003, the U.S. District 
Court for the Western District of New York entered a judgment of 
conviction against Dr. Norman for this offense.
    The basis of this conviction was Dr. Norman's creation and 
submission of falsified study data in required reports to the sponsor 
of an investigational new drug application (IND) study, in violation of 
section 505(i) of the act (21 U.S.C. 355(i)) and 21 CFR 312.62(a) and 
(b). Dr. Norman failed to conduct the study according to the approved 
protocol, reported the enrollment of nonexistent subjects in the study, 
and fabricated all of the pertinent study records associated with these 
subjects. Dr. Norman's failure to comply with the requirements of the 
act and FDA regulations concerning the conduct of an IND study is the 
type of conduct that undermines confidence in the results of clinical 
studies that are relied on in the approval process for drug products.
    As a result of Dr. Norman's conviction, FDA sent to Dr. Norman, by 
certified letter on October 10, 2007, a proposal to debar Dr. Norman 
for 5 years from providing services in any capacity to a person that 
has an approved or pending drug product application. The letter also 
offered Dr. Norman notice of an opportunity for a hearing on the 
proposal in accordance with section 306 of the act (21 U.S.C. 335a) and 
21 CFR part 12. FDA based the debarment proposal on the findings, under 
section 306(b)(2)(B)(i)(I) of the act, that Dr. Norman was convicted of 
a misdemeanor under Federal law for conduct relating to the development 
or approval, including the process for development or approval, of a 
drug product or otherwise relating to the regulation of drug products 
under the act, and that the type of conduct which served as the basis 
for the conviction undermines the process for the regulation of drugs. 
The letter notified Dr. Norman that he had 30 days from the date of 
receipt of the letter to request a hearing. Dr. Norman did not request 
a hearing. His failure to request a hearing constitutes a waiver of his 
opportunity for a hearing and a waiver of any contentions concerning 
his debarment.

II. Findings and Order

    Therefore, the Acting Director, Office of Enforcement, Office of 
Regulatory Affairs, under section 306(b)(2)(B)(i)(I) of the act and 
under authority delegated to the Acting Director (Staff Manual Guide 
1410.35), finds that Dr. Allyn M. Norman has been convicted of a 
misdemeanor under Federal law for failure to maintain adequate and 
accurate records relating to the use of investigational new drugs, that 
Dr. Norman's conduct relates to the development or approval, including 
the process for development or approval, of a drug product or otherwise 
relates to the regulation of drug products under the act, and that Dr. 
Norman's conduct, which served as the basis for his conviction, is the 
type of conduct that undermines the process for the regulation of 
drugs.
    As a result of the foregoing findings, Dr. Norman is debarred for 5 
years from providing services in any capacity to a person with an 
approved or pending drug product application under sections 505, 512, 
or 802 of the act (21 U.S.C. 355, 360b, or 382), or under section 351 
of the Public Health Service Act (42 U.S.C. 262), effective (see DATES) 
(see sections 306(c)(1)(B) and (c)(2)(A)(iii) and 201(dd) of the act 
(21 U.S.C. 321(dd)). Any person with an approved or pending drug 
product application who knowingly uses the services of Dr. Norman, in 
any capacity, during his period of debarment, will be subject to civil 
money penalties (section 307(a)(6) of the act (21 U.S.C. 355b(a)(6))). 
If Dr. Norman, during his period of debarment, provides services in any 
capacity to a person with an approved or pending drug product 
application, he will be subject to civil money penalties (section 
307(a)(7) of the act). In addition, FDA will not accept or review any 
abbreviated new drug applications submitted by or with the assistance 
of Dr. Norman during his period of debarment.
    Any application by Dr. Norman for termination of debarment under 
section 306(d)(4) of the act should be identified with Docket No. FDA-
2007-N-0377 (formerly Docket No. 2007N-0299) and sent to the Division 
of Dockets Management (see ADDRESSES). All such submissions are to be 
filed in four copies. The public availability of information in these 
submissions is governed by 21 CFR 10.20(j). Publicly available 
submissions may be seen in the Division of Dockets Management between 9 
a.m. and 4 p.m., Monday through Friday.

    Dated: June 4, 2009.
Alyson L. Saben,
Acting Director, Office of Enforcement, Office of Regulatory Affairs.
[FR Doc. E9-13766 Filed 6-11-09; 8:45 am]

BILLING CODE 4160-01-S